Clinical Trial Update: A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update for the Epstein-Barr virus vaccine candidate mRNA-1195 in healthy adults shows the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection

Drugs mentioned

• mRNA-1195

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Epstein-Barr Virus Infection | Phase 1 | Status: ACTIVE_NOT_RECRUITING